If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
284
results.
Updated on
01/09/2026 [06:53:00]
Results 175 to 200 of 284
Absstract of: CN122604944A
本发明公开了PMEPA1抑制剂在治疗纤维化疾病中的应用。本发明首次揭示了PMEPA1在肺纤维化中的作用机制，并开发了靶向肺纤维化的包含PMEPA1 siRNA的脂质纳米颗粒，该脂质纳米颗粒能够定位于肺纤维化区域，并显著改善肺纤维化水平。本发明为纤维化疾病尤其是肺纤维化的治疗提供了一种有效手段，在临床上具有广阔的应用前景。
Absstract of: CN122604704A
本发明属于耳道清洗制剂技术领域，公开了一种耳道清洗液及其制备方法。该耳道清洗液，包括：羧甲基壳聚糖、透明质酸、甘油、纳米体抑菌剂0.20%‑0.80%、N,2,3‑三甲基‑2‑异丙基丁酰胺、泛醇、碳酸氢钠和水。本发明提供的耳道清洗液在即时清洁功能的基础上，利用羧甲基壳聚糖、透明质酸、甘油与纳米体抑菌剂的共同作用，使产品在冲洗、吸干或自然流出后，仍能在耳道黏膜表面形成一层极薄且牢固的附着膜。这层膜不仅能物理保护创面，还能持续释放有效成分，提高有效成分的驻留时间，实现长效抑菌。该耳道清洗液使用便捷，清洗效果优异，刺激性小，用药舒适度高。
Absstract of: CN122604736A
本发明属于生物医药技术领域，具体涉及一种载草氨酸盐的卵磷脂纳米材料及其制备方法和应用。所述载草氨酸盐（OXA）的卵磷脂纳米材料为壳‑核结构；所述壳为大豆卵磷脂和DSPE‑PEG2000形成的磷脂双层结构；所述核为草氨酸盐。本发明中的载草氨酸盐卵磷脂纳米材料LEC（OXA），以天然大豆卵磷脂为载体，既改善了天然卵磷脂基纳米材料理化性质差、稳定性低的缺陷，又解决了OXA高极性、膜穿透性弱、体内生物利用度低的问题，还实现了大豆卵磷脂抗癌与OXA抑制乳酸生成的协同增效，可靶向降低肿瘤乳酸浓度、逆转残癌微环境的DC‑T细胞免疫抑制，兼具肿瘤靶向免疫调节与抗癌性能，为肝细胞癌RFA术后残癌的临床联合免疫治疗提供了新型药物载体与治疗策略。
Absstract of: CN122608566A
本发明涉及生物医药技术领域，具体涉及一种可电离脂质化合物及其制备方法和应用。本发明提供了一种可电离脂质化合物，所述可电离脂质化合物具有一个亲水核心和三条疏水尾链，化学结构如式(I)所示：本发明提供的可电离脂质化合物搭配胆固醇或其衍生物就可以形成安全、稳定递送药物的两组分的脂质纳米颗粒，且形成的脂质纳米颗粒在多种细胞系转染中表现出高转染效率，可以转染不同部位的细胞，安全性高。
Absstract of: CN122604732A
本发明涉及核酸基因治疗技术领域，尤其涉及脂质纳米颗粒及其制备方法与应用。本发明提供的脂质纳米颗粒，其包装材料阳离子脂类、中性脂类、PEG或PEG化脂类、胆固醇或其衍生物的摩尔百分比为(33～50)％：(10～13.33)％：(1.5～2)％：(38.5～51.33)％。在该摩尔百分比例范围进行靶向性LNP合成，具有更高的包封率，并且可以显著提高靶向性LNP转导效率。不仅仅能够实现颗粒的包封率和包载量提高，同时提高了T细胞的靶向功能，实现T细胞的高效率转染。
Absstract of: WO2025072623A1
The present invention relates to methods and compositions comprising a delivery vehicle conjugated to a cell targeting domain, wherein the delivery vehicle comprises at least one agent, and wherein the targeting domain specifically binds to the surface of a target immune cell and releases the at least one agent into the target immune cell. The invention also relates to methods for treating or preventing diseases and disorders, including cancers, infectious diseases, and immunological disorders, using the described compositions.
Absstract of: WO2025042791A1
The disclosure provides for compositions that comprise nanocomplexes formed by complexing one or more therapeutic agents with nucleic acid fragments of varying lengths and sizes that are coated or complexed with protamine sulfate, and uses thereof, including for the treatment of cancer in a subject in need thereof.
Absstract of: TR2026012628A2
Buluş özellikle, X-ışınlarını seçici olarak soğurarak doku kontrastını (görünürlüğünü) arttırmak üzere, yüksek atom numarasına sahip bizmut nanopartikülleri ile güçlendirilmiş karbomer bazlı bir polimerik matris ve radyasyonun ciltte oluşturduğu serbest radikalleri nötralize ederek hücresel hasarı ve radyasyon yanıklarını önlemek üzere, sinerjik etkili antioksidan sistem (Melatonin ve E Vitamini) içeren hidrojel formülasyonu ve ilgili formülasyon üretim yöntemi ile ilgilidir.
Absstract of: CN122609644A
本发明涉及一种多肽凝聚体及其制备方法和应用，所述多肽凝聚体为，由融合多肽TAT‑n×NoLS在含有Tris‑HCl、NaCl以及聚乙二醇8000的溶液中，于室温下孵育，自组装形成的体外相分离凝聚体结构，所述多肽凝聚体能够包载核酸或蛋白质并将其递送至细胞中，其中，所述融合多肽TAT‑n×NoLS由具有相分离特性的NoLS多肽序列经n次串联形成n×NoLS模块，n=2‑5；并在N端融合至少一个TAT穿膜肽序列；所述NoLS多肽的序列如SEQ ID NO.1所示，所述TAT穿膜肽的序列如SEQ ID NO.2所示。本发明提供的TAT‑3xNoLS多肽凝聚体具有对核酸和蛋白类生物大分子的装载、胞内递送及功能输出能力，在生物大分子递送方面表现出较好的应用潜力，也为后续开展多功能化拓展与机制优化研究提供了实验基础。
Absstract of: US20260242498A1
The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of use for delivery of cargo to brain tissue. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.
Absstract of: US20260242784A1
The present invention provides an interfering RNA for inhibiting B7-H3 expression, use thereof, and a method for preparing cells with reduced B7-H3 expression. The interfering RNA is siRNA, a target sequence of which comprises nucleotide sequences set forth in SEQ ID NOs: 1-25. The interfering RNA can effectively inhibit B7-H3 gene expression, thus being useful for preventing or treating B7-H3 related diseases.
Absstract of: WO2026171131A1
Provided in the present invention is an interleukin 2 (IL-2) conjugate containing an isolated and purified IL-2 polypeptide, and a conjugated moiety attached to a position where the amino acid residue is cysteine on the IL-2 polypeptide sequence, wherein the conjugated moiety contains a vesicle. Using the steric hindrance specificity of the vesicle, on the one hand, the interleukin-2 conjugate of the present invention enables the IL-2 polypeptide to bind to IL-2Rα on the surface of Treg cells, and on the other hand, the IL-2 conjugate of the present invention can simultaneously reduce the binding thereof to IL-2Rβ and/or IL-2Rγ and/or IL-2Rβγ on the surface of CD8 T cells. As a result, the conjugate selectively binds to and activates the Treg cells, promotes the proliferation thereof and the activation of intracellular signaling pathways, and attenuates the activation of the CD8 T cells, thereby regulating the immune microenvironment and maintaining the immunologic balance.
Absstract of: AU2025225163A1
This disclosure provides methods of increasing in vivo transfection efficiency and pharmacologic activity of T cells, by administering multiple small doses within a compact time period of T cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor that recognizes an antigen of a cell against which immune activity is to be directed. Also provided are methods of depleting B cells, and methods of treating B cell-mediated diseases and disorders by depleting B cells and achieving immunological reset, entailing administration of immune cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor recognizing a B cell marker as multiple small doses within a compact time period. The antigen receptor can be a T cell receptor or a chimeric antigen receptor.
Absstract of: WO2026170677A1
Disclosed in the present invention are a J-aggregation-induced emission photosensitizer with NIR-II emission, and a pharmaceutical composition constructed thereby, a preparation method therefor and the use thereof. The photosensitizer can produce cytotoxic type I active oxygen upon light irradiation, and exhibits excellent fluorescence imaging capability in an NIR-II region and superior phototherapeutic performance. The photosensitizer is further co-assembled with sorafenib into a pharmaceutical composition, which has J-aggregation-induced secondary self-assembly property, enables long-term imaging at a tumor site, fulfills dual functions of NIR-II fluorescence imaging and tumor therapy, and exhibits good stability and low toxic and side effects, thereby holding a wide prospect for clinical application.
Absstract of: WO2026171285A1
Provided are a preparation method for a cellulose nanocrystal-based hydrogel, and an application thereof. The hydrogel preparation method comprises: (1) adding cerium ions to a cellulose nanocrystal (CNC) suspension, and controlling the pH to be neutral, to obtain a cerium oxide-modified CNC suspension; (2) mixing the modified CNC suspension in step (1) with a CNC suspension which has not undergone the modification in step (1), to obtain a CNC mixed suspension; and (3) mixing the CNC mixed suspension in step (2) with a prepolymer, and irradiating with ultraviolet light, to obtain a hydrogel.
Absstract of: WO2026171211A1
Disclosed are a hMPV fusion protein F variant, an mRNA vaccine, and a use thereof. The hMPV fusion protein F variant has an amino acid residue difference at one or more sites relative to an hMPV fusion protein F having the accession number AGJ74096.1 in the GenBank database, wherein the amino acid sequence of the hMPV fusion protein F variant is as shown in SEQ ID NO: 1 or 2. The mRNA vaccine designed on the basis of the hMPV fusion protein F variant can induce a strong specific antibody response, and the persistence of an antibody in vivo is strong. The induced antibody can better neutralize an hMPV strain and control the amplification of the hMPV in the lungs. Therefore, the specific antibody induced by the mRNA vaccine provides an effective basis for prevention of hMPV infection-related diseases and development of combination vaccines.
Absstract of: WO2026174151A1
The present disclosure provides novel polymer-conjugated lipids conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations, including multiple doses of the LNP formulations.
Absstract of: WO2026171955A1
The present invention relates to a "one-pot" method for preparing an aqueous composition of nanoparticles of copolymers with amphiphilic blocks and comprising polypeptide units, said nanoparticles comprising at least one active principle encapsulated therein, said method comprising: - at least one step (E1) consisting in preparing a solution (S1) comprising at least one active principle and at least one hydrophilic polymer (P1) comprising at least one amine function; and - at least one step (E2), in an aqueous solvent, consisting in placing the solution (S1) in the presence of at least one hydrophobic α-amino acid N-carboxyanhydride monomer.
Absstract of: WO2026173309A1
The present invention relates to naltrexone-fatty acid conjugate nanoparticles and a long-acting injection thereof. More specifically, the present invention provides naltrexone-fatty acid conjugate nanoparticles and a long-acting injection composition thereof, the nanoparticles comprising a naltrexone-fatty acid conjugate in which a fatty acid is bonded to naltrexone or a pharmaceutically acceptable salt thereof, and being formed by self-assembly of the conjugate according to a pH change. The composition according to the present invention has improved bioavailability, half-life, injectability, and the like, and exhibits excellent long-term sustained release characteristics, and thus can improve medication compliance of patients with alcohol dependence or opioid dependence.
Absstract of: US20260240889A1
Methods and compositions for the transamniotic delivery of mRNA encoding alpha-1 antitrypsin protein to a fetus for the prenatal treatment of alpha-1 antitrypsin deficiency.
Absstract of: WO2026171948A1
The present invention relates to a "one-pot" method for preparing an aqueous solution of nanoparticles of copolymers with amphiphilic blocks and comprising polypeptide units, said nanoparticles comprising a chemical agent grafted thereto, said method comprising: • at least one step (E1), in an aqueous solvent, consisting in placing at least one hydrophilic polymer of formula (I): A-NH2, wherein A represents a natural or synthetic polymeric radical comprising the repetition of at least one unit selected from the group consisting of acrylates, ethylenes, oxyalkylenes, ethers, esters, sugars and amino acids, in the presence of at least one hydrophobic α-amino acid N-carboxyanhydride monomer, in order to obtain a copolymer of formula (II), and • at least one functionalization step (E2), in an aqueous solvent, consisting in placing said copolymer of formula (II) in the presence of a chemical agent comprising at least one carboxylic acid function or carboxylic acid derivative function allowing coupling with said copolymer of formula (II).
Absstract of: WO2026172347A1
A copolymer nanohydrogel comprising chains made of structural units corresponding to (i) at least one macromonomer consisting of a polyether block copolymer with acrylamide end groups, and (ii) an N-alkylated (meth)acrylamide monomer; characterized in that the chains of the copolymer nanohydrogel are connected by at least one crosslinker that contains biodegradable ester bond. A nanohydrogel comprising poorly water-soluble pharmaceutically active compound, a process for preparing the nanohydrogel, pharmaceutical composition thereof, and method of using the nanohydrogels are also provided by the invention.
Absstract of: WO2026174041A1
Porous nanofibrous/microfibrous spheres are provided as well as methods of use thereof and methods of making. In certain embodiments, the method of synthesis comprises a) applying inner air, outer air, and a nanofiber/microfiber suspension to a sphere generator, wherein the nanofiber/microfiber suspension comprises nanofiber/microfiber segments, and b) collecting the spheres from an outlet nozzle of the sphere generator in a media having a temperature of less than about -20°C (e.g., liquid nitrogen), thereby synthesizing the porous nanofibrous/microfibrous spheres.
Absstract of: WO2026170578A1
The present invention belongs to the technical field of the preparation of Dendrobium officinale polysaccharides, and specifically relates to a Dendrobium officinale polysaccharide nanoparticle and a preparation method therefor. The method for preparing the Dendrobium officinale polysaccharide nanoparticle comprises: firstly, extracting Dendrobium officinale polysaccharides by using a non-ionic surfactant-assisted ultrasonic-complex enzyme method, and purifying same to obtain a Dendrobium officinale polysaccharide extract; then dissolving the Dendrobium officinale polysaccharide extract in water to obtain solution 1; dissolving a modified polyacrylic resin in an organic solvent to obtain solution 2; dropwise adding solution 1 to solution 2 under stirring, and performing ultrasonic treatment for 20-30 min after the dropwise addition; and performing spray drying to obtain the final product. The method for extracting Dendrobium officinale polysaccharides provided in the present invention can effectively increase the yield of polysaccharides, and can also improve the inhibition rate of the Dendrobium officinale polysaccharide extract against α-glucosidase. The prepared Dendrobium officinale polysaccharide extract nanoparticle exhibits a good hypoglycemic effect.
Nº publicación: WO2026174220A1 20/08/2026
Applicant:
MASSACHUSETTS INST OF TECHNOLOGY [US]
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Absstract of: WO2026174220A1
Single polymer chain nanoparticles (SPCNs) formed by a random heteropolymer composed of three or more components have been developed and shown to display similar levels of hydration frustration as proteins. These SPCNs can be categorized into three types, based on whether either hydrophobic or hydrophilic residues, or both types, display frustrated states. A series of physicochemical rules that determine the state of these SPCNs are proposed. The generality of these rules are demonstrated via atomistic molecular dynamics simulations and simplified Monte Carlo models of SCPNs with different backbones and residues. This disclosure provides insights into the design of SPCNs, an emerging polymer modality that achieves the ease and cost of fabrication of polymeric material with the functionality of biological proteins.
BOPI
Electronic site
